Leronlimab
- Generic Name
- Leronlimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 674782-26-4
- Unique Ingredient Identifier
- Y1J4NP8FF0
- Background
Leronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn. It was first described in the literature in 2001. This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.
- Indication
Leronlimab is currently being investigated for the treatment of a number of cancers and HIV.
...
- Associated Conditions
- -
- Associated Therapies
- -
Leronlimab in Patients With Coronavirus Disease 2019 (COVID-19) With Need for Mechanical Ventilation or Extracorporeal Membrane Oxygenation
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Hospital Israelita Albert Einstein
- Target Recruit Count
- 316
- Registration Number
- NCT04901689
- Locations
- 🇧🇷
Hospital do Coração do Brasil, Brasilia, DF, Brazil
🇧🇷Hospital 9 de Julho, Sao Paulo, Please Select, Brazil
🇧🇷Santa Casa de Misericórdia de Passos, Passos, MG, Brazil
Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia
- First Posted Date
- 2021-05-25
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Hospital Israelita Albert Einstein
- Target Recruit Count
- 612
- Registration Number
- NCT04901676
- Locations
- 🇧🇷
Clinica São Roque, Ipiaú, BA, Brazil
🇧🇷Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel, Salvador, BA, Brazil
🇧🇷Instituto de Ensino e Pesquisa do Hospital da Bahia, Salvador, BA, Brazil
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- CytoDyn, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04504942
- Locations
- 🇺🇸
Quest Clinical Research, San Francisco, California, United States
A Compassionate Use Study of Leronlimab in Breast Cancer
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- CytoDyn, Inc.
- Registration Number
- NCT04313075
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.